
June 9 (Reuters) - Pfizer PFE.N and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an industry conference.
The meetings focused on high-level ideas and were not digging into any substance yet, Bourla said.
President Donald Trump issued an executive order last month aimed at lowering the prices of branded medicines for U.S. consumers.